In this article we will explore 8A-PDHQ, a topic of great relevance today that impacts various areas of study and that has generated broad interest in the academic community and society in general. 8A-PDHQ represents a crucial point to understand the functioning of different phenomena, from a historical, scientific, social or cultural perspective. Through detailed analysis, we will examine each relevant aspect of 8A-PDHQ, exploring its implications, its evolution over time, as well as possible solutions or approaches to address this challenge. This article aims to offer a comprehensive, critical and reflective vision about 8A-PDHQ, in an effort to provide knowledge and generate an informed debate on this important topic.
![]() | |
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C15H21N |
Molar mass | 215.340 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
8a-Phenyldecahydroquinoline (8A-PDHQ) is a high affinity NMDA antagonist developed by a team at Parke Davis in the 1950s.[1] It is a structural analog of phencyclidine with slightly lower binding affinity than the parent compound. (−)-8a-Phenyldecahydroquinoline has an in vivo potency comparable to that of (+)-MK-801.[2][3]